GALLIUM DOTATATE GA-68 - Generic Drug Details
What are the generic sources for gallium dotatate ga-68 and what is the scope of patent protection?
Gallium dotatate ga-68
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for GALLIUM DOTATATE GA-68
| International Patents: | 32 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 21 |
| DailyMed Link: | GALLIUM DOTATATE GA-68 at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for GALLIUM DOTATATE GA-68
Generic Entry Date for GALLIUM DOTATATE GA-68*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for GALLIUM DOTATATE GA-68
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Akiva Mintz | PHASE2 |
| Joshua Palmer | PHASE1 |
| National Cancer Institute (NCI) | PHASE1 |
US Patents and Regulatory Information for GALLIUM DOTATATE GA-68
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | NETSPOT | gallium dotatate ga-68 | POWDER;INTRAVENOUS | 208547-001 | Jun 1, 2016 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for GALLIUM DOTATATE GA-68
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2012297008 | ⤷ Start Trial | |
| Brazil | 112014003336 | ⤷ Start Trial | |
| Brazil | 122020011908 | ⤷ Start Trial | |
| Canada | 2844145 | ⤷ Start Trial | |
| Canada | 3045484 | ⤷ Start Trial | |
| China | 103889930 | ⤷ Start Trial | |
| Colombia | 7020857 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Gallium Dotatate Ga-68 Market Dynamics, Patent Position, and Financial Trajectory
Gallium dotatate Ga-68 is marketed in the United States as NETSPOT, a diagnostic radiopharmaceutical used for positron emission tomography (PET) imaging of somatostatin receptor-positive neuroendocrine tumors (NETs). Its commercial value is tied to the growth of NET diagnosis, staging, treatment selection, and surveillance rather than to drug treatment revenue. Novartis owns the commercial franchise through Advanced Accelerator Applications, but does not separately disclose NETSPOT revenue in public financial reporting.
The product has durable clinical relevance because it supports the use of somatostatin receptor-targeted therapies, including Lutathera, while competing against other PET tracers and conventional imaging. Its principal commercial constraints are isotope availability, short shelf life, manufacturing logistics, imaging-center access, and reimbursement.
What is gallium dotatate Ga-68 and how is NETSPOT used?
Gallium dotatate Ga-68 is a radiolabeled somatostatin analog. The Ga-68 isotope binds to somatostatin receptor subtype 2, which is commonly expressed on well-differentiated gastroenteropancreatic and other neuroendocrine tumors. PET imaging then identifies receptor-positive lesions.
NETSPOT is supplied as a kit for preparation of gallium Ga-68 dotatate injection. It is not administered as a therapeutic radiopharmaceutical. The product is used for:
- Localization of somatostatin receptor-positive primary and metastatic NETs.
- Staging and restaging.
- Treatment planning for peptide receptor radionuclide therapy.
- Post-treatment surveillance.
- Evaluation of suspected recurrence.
The FDA approved NETSPOT on June 1, 2016, under NDA 208547. The approval followed the orphan-drug framework and established gallium Ga-68 dotatate as the first FDA-approved Ga-68 PET agent for somatostatin receptor imaging in the United States (FDA, 2016).
What is the difference between gallium dotatate Ga-68 and Lutathera?
NETSPOT and Lutathera use the same general targeting concept but have different commercial roles.
| Attribute | NETSPOT | Lutathera |
|---|---|---|
| Active radiolabeled agent | Ga-68 dotatate | Lu-177 dotatate |
| Primary role | Diagnostic imaging | Therapeutic radioligand therapy |
| FDA approval | 2016 | 2018 |
| Company | Novartis through AAA | Novartis through AAA |
| Revenue model | Imaging procedure and radiopharmaceutical supply | High-value treatment course |
| Clinical linkage | Identifies receptor-positive disease | Treats receptor-positive disease |
NETSPOT can support patient selection for Lutathera, although the FDA labeling does not make NETSPOT use a universal prerequisite for treatment. The two products therefore create a vertically integrated diagnostic-to-therapy pathway for Novartis.
What is the FDA regulatory status of gallium dotatate Ga-68?
NETSPOT is FDA-approved and commercially available in the United States. It is classified as a diagnostic radiopharmaceutical kit rather than a conventional small-molecule therapeutic.
The product’s regulatory characteristics include:
| Regulatory item | Status |
|---|---|
| Brand | NETSPOT |
| Active ingredient | Gallium Ga-68 dotatate |
| FDA application | NDA 208547 |
| Approval date | June 1, 2016 |
| Sponsor at approval | Advanced Accelerator Applications USA, Inc. |
| Current corporate owner | Novartis |
| Therapeutic category | Diagnostic PET radiopharmaceutical |
| Orphan-drug designation | Yes |
| Administration | Intravenous injection after kit radiolabeling |
The FDA label states that the kit must be radiolabeled with Ga-68 chloride and used under controlled preparation conditions. The short physical half-life of Ga-68, approximately 68 minutes, makes distribution and scheduling different from conventional pharmaceuticals (FDA, 2023).
When does gallium dotatate lose exclusivity?
NETSPOT’s principal regulatory exclusivity period was orphan-drug exclusivity, which generally lasted seven years from the approval date. Based on the June 1, 2016 approval date, the seven-year orphan exclusivity period would have ended on June 1, 2023, subject to the exact scope of the designation and any applicable regulatory events.
There is no conventional biosimilar pathway for NETSPOT because it is not a biologic. Competitive entry would more likely occur through:
- An abbreviated new drug application, if an applicant can establish pharmaceutical equivalence and the relevant regulatory pathway.
- A separate 505(b)(2) application for a comparable Ga-68 somatostatin-receptor PET product.
- Competing radiopharmaceutical products with a different formulation, kit, isotope source, or labeling approach.
- Compounded or hospital-prepared products where legally permitted and operationally feasible.
Regulatory exclusivity has therefore become less important than manufacturing capability, isotope supply, institutional contracts, reimbursement, and physician adoption.
What patents protect gallium dotatate Ga-68 and NETSPOT?
The commercial protection for NETSPOT is more difficult to assess than for a conventional oral drug because the product depends on a kit, radiolabeling process, imaging indication, and highly specialized distribution system.
Publicly available FDA materials identify NETSPOT as an approved product, but the commercial franchise does not have the same patent visibility as many blockbuster therapeutic products. The key protection layers are likely to include:
- Composition and ligand patents covering dotatate or related somatostatin analogs.
- Radiolabeling and kit-formulation patents.
- Manufacturing and quality-control processes.
- Method-of-use claims for receptor-positive NET imaging.
- Know-how involving isotope production, release testing, logistics, and clinical implementation.
The presence of a patent family does not necessarily block a competing Ga-68 dotatate product after orphan exclusivity expires. A competitor can design around formulation, sourcing, kit configuration, or process claims, while method-of-use claims may face validity, written-description, enablement, or obviousness challenges.
What is the Orange Book status of NETSPOT?
The FDA Orange Book should be reviewed for the current patent and exclusivity record associated with NDA 208547. Unlike many high-revenue small-molecule drugs, NETSPOT has not been broadly associated with a highly visible Orange Book patent litigation campaign or a major publicly reported Paragraph IV dispute.
The strategic implication is important: the principal barrier to entry may be operational rather than purely patent-based. A competitor must produce a consistent radiopharmaceutical kit, secure Ga-68 supply, qualify nuclear pharmacies or manufacturing sites, meet short release timelines, and obtain reimbursement at sufficient margins.
Are there Paragraph IV challenges to gallium dotatate Ga-68?
No major publicly reported Paragraph IV litigation campaign against NETSPOT has become a defining feature of the product’s market history through the publicly documented period.
A Paragraph IV challenge would require an ANDA applicant to certify that relevant patents are invalid, unenforceable, or not infringed. The commercial attractiveness of such a filing is limited by several factors:
- The addressable market is smaller than that of mass-market pharmaceuticals.
- Radiopharmaceutical distribution is geographically constrained.
- Product value depends on same-day or near-term delivery.
- Manufacturing sites must meet radioactive-material and drug-quality requirements.
- Hospitals may prefer established suppliers because supply interruption affects scheduled imaging.
- A challenger may face limited benefit from a conventional “launch at risk” strategy if the incumbent retains clinical and contracting advantages.
The absence of prominent litigation does not eliminate entry risk. It indicates that regulatory execution, supply infrastructure, and local market access may be more decisive than patent litigation.
What formulations are protected by NETSPOT?
NETSPOT is a radiolabeling kit rather than a ready-to-inject product containing a long-lived active ingredient. The kit includes components used to prepare Ga-68 dotatate injection at or near the administration site.
Formulation and manufacturing protection may cover:
- The dotatate precursor.
- Buffering and stabilizing agents.
- Vial configuration.
- Radiolabeling conditions.
- Purification and quality-control specifications.
- Limits for radiochemical purity and chemical impurities.
- Storage and handling requirements before and after labeling.
The short half-life of Ga-68 reduces the value of conventional centralized finished-dose inventory. Commercial success depends on a distributed model involving generators or cyclotrons, radiopharmacies, hospital nuclear-medicine departments, and validated release procedures.
How does the Ga-68 supply chain affect market dynamics?
Ga-68 is produced primarily from Ge-68/Ga-68 generators or from cyclotron-based production. Supply economics directly affect NETSPOT because the isotope decays rapidly and cannot be stored like a conventional drug.
Key supply-chain variables include:
| Variable | Commercial effect |
|---|---|
| Generator availability | Determines local or regional production capacity |
| Cyclotron access | Expands supply in centers with suitable infrastructure |
| Physical half-life | Limits shipping distance and inventory flexibility |
| Radiopharmacy network | Determines patient access and scheduling |
| Quality release timing | Affects same-day administration |
| Isotope demand | Creates competition with other Ga-68 products |
| Hospital infrastructure | Limits adoption in smaller facilities |
The market favors suppliers with validated nuclear-pharmacy networks and multiple production sites. A product with identical clinical performance can still lose share if it has lower delivery reliability.
How large is the commercial market for gallium dotatate Ga-68?
The Ga-68 dotatate market is a specialized segment within the broader radiopharmaceutical and molecular-imaging market. Demand is driven by:
- Rising incidence and diagnosis of NETs.
- Greater use of PET over older somatostatin-receptor imaging techniques.
- Expansion of NET centers of excellence.
- Increased use of receptor imaging before radioligand therapy.
- Improved recognition of metastatic and recurrent disease.
- Growth in radioligand therapy capacity.
The product does not generate the same revenue profile as a therapeutic drug because each patient generally receives an imaging dose rather than a prolonged course of treatment. Revenue is linked to completed scans, radiopharmaceutical reimbursement, hospital contracts, and geographic coverage.
The broader NET market remains attractive because diagnostic imaging can create downstream demand for surgery, somatostatin analogs, systemic therapy, and Lutathera. The commercial value of NETSPOT is therefore partly direct and partly strategic.
What is the financial trajectory of NETSPOT?
Novartis does not separately report NETSPOT revenue in its standard public financial statements. The company reports radioligand therapy and related business performance at a level that emphasizes products such as Lutathera and Pluvicto rather than providing a standalone NETSPOT income statement.
The most defensible financial assessment is therefore qualitative:
2016-2018: Market creation
NETSPOT established the U.S. commercial category for Ga-68 somatostatin-receptor PET imaging. Early growth depended on physician education, payer coverage, radiopharmacy development, and the replacement of older imaging methods.
2019-2021: Adoption and network expansion
Use expanded as more nuclear-medicine centers gained access to Ga-68 supply and clinicians incorporated receptor imaging into NET evaluation. Novartis’ acquisition of AAA strengthened the link between diagnostic imaging and Lutathera treatment.
2022-2024: Maturity and ecosystem value
The product moved toward a mature diagnostic franchise. Growth became more dependent on scan volume, geographic expansion, and radioligand-therapy referral pathways than on first-time market education. Competition from other somatostatin-receptor PET agents and alternative Ga-68 products became more relevant.
NETSPOT is strategically valuable even without separately disclosed blockbuster revenue because it can influence the treatment pathway for Novartis’ radioligand therapy franchise. Its economic contribution includes direct imaging sales, customer retention, referral generation, and institutional relationships.
Which companies are challenging the gallium dotatate Ga-68 market?
Competitive pressure comes from both direct and indirect sources.
Direct competitors
Potential direct competitors include manufacturers of:
- Ga-68 dotatate products.
- Ga-68 DOTATOC products.
- Other Ga-68 somatostatin-receptor PET agents.
- Cyclotron-produced or generator-produced Ga-68 products.
- Hospital or regional radiopharmacy preparations.
The most relevant comparison is not always molecule-to-molecule identity. Physicians and hospitals may choose among products based on availability, image quality, labeling workflow, reimbursement, and delivery reliability.
Indirect competitors
Indirect competitors include:
- Cu-64 somatostatin-receptor PET agents, which have a longer half-life.
- Conventional CT and MRI.
- In-111 octreotide scintigraphy.
- FDG PET in selected NET populations.
- Other diagnostic pathways used for staging and surveillance.
Cu-64 products may reduce dependence on same-day Ga-68 logistics because the isotope has a longer half-life. This can improve shipping flexibility and broaden geographic reach, although clinical selection depends on tumor biology, institutional protocols, and payer policy.
What generic launch risks exist for NETSPOT?
A generic or follow-on launch could occur without immediately displacing NETSPOT. The main risks to the incumbent are:
- Price competition in high-volume metropolitan markets.
- Hospital contracting based on radiopharmacy supply reliability.
- Substitution by locally produced Ga-68 products.
- Increased use of alternative receptor-targeting PET agents.
- Loss of diagnostic control over patients later referred for Lutathera.
- Payer preference for lower-cost equivalent imaging.
The main barriers facing a challenger are radioactive-material licensing, validated radiolabeling, supply-chain density, reimbursement contracting, technical support, and the need to deliver product within a narrow time window.
What patent litigation and settlement agreements affect NETSPOT?
No major settlement agreement or high-profile patent litigation involving NETSPOT has materially reshaped its market position in the publicly reported record through 2024. The absence of a prominent litigation history reduces the visibility of a traditional patent cliff.
Market risk is more likely to emerge from regulatory approvals, supplier agreements, technology changes, and reimbursement decisions than from a single court settlement. Novartis’ control of both NETSPOT and Lutathera also creates a commercial incentive to preserve reliable receptor imaging capacity even if direct NETSPOT margins moderate.
How strong is the patent estate for gallium dotatate Ga-68?
The patent estate is best characterized as moderate in strategic value but less decisive than the patent estates surrounding high-value chronic therapies.
Strengths include:
- Specialized formulation and radiolabeling know-how.
- Manufacturing complexity.
- Potential method-of-use protection.
- Integration with nuclear-pharmacy infrastructure.
- Clinical familiarity and established protocols.
- Linkage to the Lutathera treatment pathway.
Weaknesses include:
- Expiration or reduced relevance of early composition patents.
- Limited value of conventional exclusivity after orphan exclusivity ended.
- Possible design-around opportunities.
- Competition from different isotopes and ligands.
- Lack of a durable biologic-style exclusivity framework.
- Short product shelf life, which encourages local alternatives.
The product’s competitive moat is therefore a combination of regulatory experience, supply reliability, clinical adoption, and commercial integration rather than patents alone.
What is the geographic coverage of NETSPOT?
NETSPOT’s practical geographic coverage depends on the location of qualified radiopharmacies, Ga-68 generators, cyclotrons, nuclear-medicine departments, and approved distribution channels.
Coverage is strongest in:
- Major academic medical centers.
- Urban hospital systems.
- NET referral centers.
- Regions with established radiopharmacy networks.
- Markets with access to Ga-68 production infrastructure.
Rural and lower-volume regions face greater access constraints because the product must be prepared, released, transported, and administered within a short period. Regional production and alternative longer-lived isotopes can improve access.
Key Takeaways
- Gallium dotatate Ga-68 is marketed in the United States as NETSPOT, a diagnostic PET radiopharmaceutical for somatostatin receptor-positive NETs.
- FDA approval occurred on June 1, 2016, under NDA 208547.
- Seven-year orphan-drug exclusivity would have expired in June 2023.
- NETSPOT is not a biologic and has no biosimilar pathway.
- Publicly reported financial statements do not provide standalone NETSPOT revenue.
- Its financial value is linked to scan volume, reimbursement, radiopharmacy access, and support for Lutathera utilization.
- No major publicly reported Paragraph IV campaign or patent settlement has defined the product’s market.
- The strongest barriers are isotope supply, radiopharmacy infrastructure, manufacturing quality, logistics, and clinical adoption.
- Competition includes other Ga-68 receptor-targeting products, Cu-64 PET agents, MRI, CT, In-111 imaging, and FDG PET.
- Novartis’ ownership of both NETSPOT and Lutathera gives the product strategic value beyond direct diagnostic sales.
FAQs
Is gallium dotatate Ga-68 the same as NETSPOT?
NETSPOT is the U.S. brand for a kit used to prepare gallium Ga-68 dotatate injection. Gallium dotatate Ga-68 is the radiolabeled imaging agent produced from the kit.
Is NETSPOT a cancer treatment?
No. NETSPOT is a diagnostic imaging product. Lutathera is the related therapeutic radioligand used to treat certain somatostatin receptor-positive NETs.
Can hospitals compound gallium dotatate Ga-68?
Hospital or radiopharmacy preparation may be possible under applicable FDA, state, radiation-safety, and pharmacy rules. The legal and operational framework depends on the preparation model, facility licensing, and product status.
Does NETSPOT require a PET scan?
Yes. NETSPOT is administered intravenously and detected using PET imaging, generally with computed tomography or another anatomical imaging component.
Is Cu-64 dotatate a substitute for Ga-68 dotatate?
Cu-64 somatostatin-receptor PET can be an alternative in appropriate clinical settings. Its longer half-life may improve distribution and scheduling, but product selection depends on clinical protocols, regulatory labeling, reimbursement, and local availability.
References
-
U.S. Food and Drug Administration. (2016). FDA approves new imaging drug for neuroendocrine tumors. https://www.fda.gov/news-events/press-announcements/fda-approves-new-imaging-drug-neuroendocrine-tumors
-
U.S. Food and Drug Administration. (2023). NETSPOT (kit for the preparation of gallium Ga 68 dotatate injection) prescribing information. Advanced Accelerator Applications USA, Inc.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/financial-data/annual-report
-
U.S. Food and Drug Administration. (2018). FDA approves Lutathera for treatment of certain neuroendocrine tumors. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutathera-treatment-certain-neuroendocrine-tumors
-
National Cancer Institute. (2024). Neuroendocrine tumors treatment. https://www.cancer.gov/types/neuroendocrine-tumorsેશન
More… ↓
